AlphaMadera's AlphaVal page computes Pfizer Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag PFE as undervalued, fairly valued, or overvalued.

What is Pfizer Inc.'s fair value?

Fair value for PFE is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value PFE?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from PFE's most recent reported fundamentals.

PFE - Pfizer Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $26.75 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Fair Value Moderate

Trading 18.9% below fair value

Current Price $25.08

Bear Case $26.50 5.7% upside ($26.50 - $25.08) / $25.08 = 5.7% $2.34 × 12x P/E

Fair Value $30.92 23.3% upside ($30.92 - $25.08) / $25.08 = 23.3% $2.34 × 14x P/E

Bull Case $35.34 40.9% upside ($35.34 - $25.08) / $25.08 = 40.9% $2.34 × 16x P/E

Adjust Assumptions

P/E Multiple

14.0x

Adjusted EPS

2.34$

Key Value Driver

Normalized P/E multiple (14x base case)

Implied Market Multiple 10.7x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $26.75 from 39 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $30.92 per share.

Warnings

⚠ The company's reported profits differ from official accounting profits by 72%. Check what costs are being left out of the adjusted number.

⚠ The company pays out 126% of its profits as dividends. That leaves little cushion — the dividend could be cut if business slows down.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples